HUP0301102A2 - Emlős citokinok; kapcsolódó reagensek és eljárások - Google Patents

Emlős citokinok; kapcsolódó reagensek és eljárások

Info

Publication number
HUP0301102A2
HUP0301102A2 HU0301102A HUP0301102A HUP0301102A2 HU P0301102 A2 HUP0301102 A2 HU P0301102A2 HU 0301102 A HU0301102 A HU 0301102A HU P0301102 A HUP0301102 A HU P0301102A HU P0301102 A2 HUP0301102 A2 HU P0301102A2
Authority
HU
Hungary
Prior art keywords
interleukin
antibodies
combinations
pharmaceutical compositions
mammalian
Prior art date
Application number
HU0301102A
Other languages
English (en)
Inventor
Rene De Waal Malefyt
Robert A. Kastelein
Sergio A. Lira
Satwant K. Narula
Birgit Oppmann
Donna M. Rennick
Maria T. Wiekowski
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26860707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0301102(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0301102A2 publication Critical patent/HUP0301102A2/hu
Publication of HUP0301102A3 publication Critical patent/HUP0301102A3/hu
Publication of HU230679B1 publication Critical patent/HU230679B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)

Abstract

A találmány valamely emlősből eredő citokint kódoló tisztítottgénekkel, az ezekhez kapcsolódó reagensekkel, ide értve a tisztítottfehérjéket is, fajlagos antitestekkel és ezt a molekulát kódolónukleinsavakkal foglalkozik. A találmány foglalkozik továbbá azemlített reagenseket és diagnosztikai készleteket alkalmazóeljárásokkal is. Ó
HU0301102A 1999-09-09 2000-09-08 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions HU230679B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39309099A 1999-09-09 1999-09-09
US16461699P 1999-11-10 1999-11-10
PCT/US2000/024686 WO2001018051A2 (en) 1999-09-09 2000-09-08 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions

Publications (3)

Publication Number Publication Date
HUP0301102A2 true HUP0301102A2 (hu) 2003-07-28
HUP0301102A3 HUP0301102A3 (en) 2005-11-28
HU230679B1 HU230679B1 (en) 2017-08-28

Family

ID=26860707

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301102A HU230679B1 (en) 1999-09-09 2000-09-08 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions

Country Status (15)

Country Link
EP (1) EP1210434B2 (hu)
JP (6) JP4505166B2 (hu)
KR (1) KR100894359B1 (hu)
CN (1) CN100529076C (hu)
AR (1) AR035560A1 (hu)
AT (1) ATE389019T1 (hu)
AU (2) AU780163B2 (hu)
CA (1) CA2388562C (hu)
DE (1) DE60038304T3 (hu)
ES (1) ES2300276T5 (hu)
HK (1) HK1044170B (hu)
HU (1) HU230679B1 (hu)
IL (1) IL148300A0 (hu)
MX (1) MXPA02002684A (hu)
WO (1) WO2001018051A2 (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202362B2 (en) * 1999-09-03 2011-06-23 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
JP5477998B2 (ja) 2002-10-30 2014-04-23 ジェネンテック， インコーポレイテッド Ｉｌ−１７産生の阻害
WO2004058178A2 (en) 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
CN1759123B (zh) * 2003-03-10 2011-04-13 先灵公司 Il-23激动剂及拮抗剂的用途；相关试剂
CA2525184C (en) 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
EP1522858A1 (en) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators
WO2005108425A1 (en) * 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006068987A2 (en) * 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
JP2009501006A (ja) 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
DE602006015830D1 (de) * 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
HUE034269T2 (hu) 2005-12-29 2018-02-28 Janssen Biotech Inc Humán anti-IL-23 ellenanyagok, készítmények, eljárások és alkalmazások
JP5175214B2 (ja) 2005-12-30 2013-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 改良された安定性を有するインターロイキン−１２ｐ４０変種
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
JP2010518856A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ＩＬ−２３ｐ１９抗体
AU2008219684B2 (en) 2007-02-28 2014-04-17 Merck Sharp & Dohme Corp. Engineered anti-IL-23R antibodies
CN103933573A (zh) 2007-02-28 2014-07-23 默沙东公司 用于治疗免疫病症的联合治疗
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
EP2305304A4 (en) * 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine IMMUNOSTIMULATOR WITH EP1 AGONIST
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US8778346B2 (en) 2010-11-04 2014-07-15 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
JP6293120B2 (ja) 2012-05-03 2018-03-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ＩＬ−２３ｐ１９抗体
EP2866833B1 (en) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
KR101625112B1 (ko) 2013-04-16 2016-05-27 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
WO2014171721A1 (ko) * 2013-04-16 2014-10-23 가톨릭대학교 산학협력단 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
CN113563478A (zh) * 2013-09-24 2021-10-29 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
EP3189153B1 (en) 2014-09-03 2021-06-16 Boehringer Ingelheim International GmbH Compound targeting il-23a and tnf-alpha and uses thereof
JP6219875B2 (ja) * 2015-04-10 2017-10-25 株式会社スクウェア・エニックス ネットワークゲームシステム、ゲーム装置及びプログラム
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN114317430A (zh) * 2021-12-28 2022-04-12 河北银丰鼎诚生物技术有限公司 一种适用于脐血来源免疫细胞扩增的培养液

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0790255B1 (en) * 1989-12-22 2007-08-08 F. Hoffmann-La Roche Ag Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5853721A (en) 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
EP0956301A2 (en) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 gene expression and delivery systems and uses
PE20000183A1 (es) * 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
AU2661199A (en) * 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods

Also Published As

Publication number Publication date
IL148300A0 (en) 2002-09-12
KR20020034185A (ko) 2002-05-08
HK1044170A1 (en) 2002-10-11
EP1210434B2 (en) 2016-12-14
DE60038304D1 (de) 2008-04-24
JP4969610B2 (ja) 2012-07-04
CN100529076C (zh) 2009-08-19
MXPA02002684A (es) 2002-07-30
HU230679B1 (en) 2017-08-28
DE60038304T3 (de) 2017-04-06
AU2008240348B2 (en) 2012-07-12
WO2001018051A2 (en) 2001-03-15
JP2015051005A (ja) 2015-03-19
EP1210434A2 (en) 2002-06-05
JP2007045830A (ja) 2007-02-22
HK1044170B (zh) 2008-08-01
DE60038304T2 (de) 2009-03-19
HUP0301102A3 (en) 2005-11-28
AR035560A1 (es) 2004-06-16
JP2013128489A (ja) 2013-07-04
AU7360800A (en) 2001-04-10
JP6140122B2 (ja) 2017-05-31
KR100894359B1 (ko) 2009-04-22
WO2001018051A3 (en) 2001-09-20
JP2003510038A (ja) 2003-03-18
ES2300276T5 (es) 2017-06-02
ES2300276T3 (es) 2008-06-16
AU780163B2 (en) 2005-03-03
CA2388562A1 (en) 2001-03-15
JP2009268467A (ja) 2009-11-19
EP1210434B1 (en) 2008-03-12
CN1387571A (zh) 2002-12-25
CA2388562C (en) 2014-07-22
JP2010233571A (ja) 2010-10-21
ATE389019T1 (de) 2008-03-15
AU2008240348A1 (en) 2008-11-27
JP4505166B2 (ja) 2010-07-21

Similar Documents

Publication Publication Date Title
HUP0301102A2 (hu) Emlős citokinok; kapcsolódó reagensek és eljárások
BR9811039A (pt) Citocina de mamìferos: interleucina-b30 e reagentes relacionados
DK0673420T3 (da) Mammale receptorer for interleukin 10 (IL-10)
EP1862472A3 (en) Chlamydia protein, gene sequence and uses thereof
ATE184052T1 (de) Gdf-1 und uog1 proteine
EP0960622A3 (en) Use of pharmaceutical compositions containing both IL-6 and IL-12 for the activation of T cells
EP1897949A3 (en) Human interleukin-B50. Therapeutic uses
EP1942114A3 (en) Mammalian cytokines; related reagents and methods
EP2292760A3 (en) Mammalian cytokines, receptors, related reagents and methods
WO2000042188A3 (en) Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
SE9602496D0 (sv) Method and means for producing a fibrinogen binding protein and its use in biotechnology
WO1998001557A3 (en) Mammalian chemokine reagents
WO1998011226A3 (en) Mammalian chemokines, related reagents
DE69739751D1 (de) Isolierte gene aus säuger monozyten und betreffende reagentien
CA2209858A1 (en) Il-2r-associated polypeptide and dna molecules coding therefor
WO2003056021A3 (en) Modified tetracycline repressor protein compositions and methods of use
ATE389018T1 (de) Cx3c chemokin-gene von säugetieren
DE69728897D1 (de) Saeugetierchemokine
WO2001064713A3 (en) Mammalian interleukin-10 (il-10) receptor variants
WO1998032858A3 (en) Mammalian chemokines; receptors; reagents; uses
BR9713632A (pt) Citocina de mamìfero relacionada com a il-10
WO2002068596A3 (en) Mammalian cytokines; related reagents
EP1905832A3 (en) Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
WO2001009176A3 (en) Mammalian cytokines; related reagents
WO2002012541A3 (en) Novel motor proteins and methods for their use

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: RATHONYI ZOLTAN, S.B.G. & K. SZABADALMI UEGYVI, HU

FH92 Termination of representative

Representative=s name: BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVI, HU

HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORP., US